Allogene Therapeutics, Inc. (NASDAQ:ALLO) Director Franz B. Humer Sells 11,200 Shares of Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLOGet Free Report) Director Franz B. Humer sold 11,200 shares of the business’s stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $2.34, for a total value of $26,208.00. Following the sale, the director now owns 255,253 shares of the company’s stock, valued at approximately $597,292.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Allogene Therapeutics Trading Up 0.4 %

NASDAQ:ALLO opened at $2.51 on Tuesday. Allogene Therapeutics, Inc. has a 1 year low of $2.23 and a 1 year high of $6.05. The stock has a market cap of $428.84 million, a price-to-earnings ratio of -1.40 and a beta of 0.90. The stock has a 50-day moving average price of $3.25 and a two-hundred day moving average price of $3.52.

Allogene Therapeutics (NASDAQ:ALLOGet Free Report) last posted its earnings results on Monday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03. Allogene Therapeutics had a negative return on equity of 50.81% and a negative net margin of 223,139.98%. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.01 million. During the same period in the previous year, the firm earned ($0.68) earnings per share. The company’s revenue was down 26.7% on a year-over-year basis. Sell-side analysts forecast that Allogene Therapeutics, Inc. will post -1.51 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on ALLO shares. Truist Financial restated a “buy” rating and set a $17.00 target price on shares of Allogene Therapeutics in a research report on Wednesday, May 15th. Piper Sandler assumed coverage on Allogene Therapeutics in a research note on Friday. They set an “overweight” rating and a $11.00 price objective for the company. Stifel Nicolaus lifted their price objective on Allogene Therapeutics from $4.40 to $4.60 and gave the stock a “hold” rating in a research note on Tuesday, May 14th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price objective on shares of Allogene Therapeutics in a research note on Friday, March 15th. Finally, Oppenheimer decreased their price objective on Allogene Therapeutics from $14.00 to $13.00 and set an “outperform” rating for the company in a research note on Tuesday, May 21st. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Allogene Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.95.

Get Our Latest Report on Allogene Therapeutics

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD grew its stake in Allogene Therapeutics by 76.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,177,619 shares of the company’s stock valued at $18,675,000 after acquiring an additional 1,806,147 shares during the period. CANADA LIFE ASSURANCE Co lifted its holdings in shares of Allogene Therapeutics by 85.1% in the first quarter. CANADA LIFE ASSURANCE Co now owns 17,750 shares of the company’s stock valued at $79,000 after purchasing an additional 8,162 shares in the last quarter. Headlands Technologies LLC bought a new stake in shares of Allogene Therapeutics in the first quarter valued at about $78,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Allogene Therapeutics in the first quarter valued at about $1,280,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Allogene Therapeutics by 85.1% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 361,913 shares of the company’s stock valued at $1,768,000 after purchasing an additional 166,433 shares in the last quarter. 83.63% of the stock is owned by institutional investors and hedge funds.

About Allogene Therapeutics

(Get Free Report)

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).

Featured Stories

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.